Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
United States: Equities favored over Treasuries – BNY

United States: Equities favored over Treasuries – BNY

FXStreetFXStreet2026/08/13 15:12

Geoff Yu at BNY argues that the loss of some U.S. exceptionalism has not translated into a broad exodus from U.S. assets. Cross-border investors maintain high U.S. equity allocations, supported by technology and AI themes, while trimming Treasury holdings as curve steepening raises duration risk. The report expects U.S. asset positioning to remain structurally firm.

Equity strength, managed duration risk

"An immediate follow-up to the loss of “U.S. exceptionalism” is whether U.S. asset dominance will also collapse. The answer remains a resolute “no”: “sell America” is still discussed far more often than it is implemented in portfolios."

"The technology and AI story underpinning U.S. equity performance remains intact and continues to dominate cross-border positioning. Our data show that U.S. equities’ share in non-U.S. portfolios has risen sharply, approaching year-to-date highs."

"Within sovereign-bond portfolios, Treasury holdings dipped, showing that curve steepening has had an impact. Even so, a week after the Fed decision, total Treasury positioning for this investor cohort remained above the early-July lows."

"We remain confident that U.S. asset positioning will stay firm for structural reasons. The positioning skew within U.S. assets also appears increasingly favorable to equities."

"Within U.S. assets, retain equity exposure but manage Treasury duration more actively, as curve steepening and fixed-income volatility remain the main pressure points."

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.

U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).

智通财经2026/09/21 07:11

Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential

According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.

智通财经2026/09/21 07:11

Autoimmune and inflammatory disease pharmaceutical company TRex Bio (TRX.US) applies for US listing, plans to raise up to 100 millions dollars.

TRex Bio filed documents with the U.S. Securities and Exchange Commission (SEC) last Friday, intending to raise up to 100 million USD through an initial public offering (IPO).

智通财经2026/09/21 07:11